MARLBOROUGH, Mass., Feb. 22,
2024 /PRNewswire/ -- Boston Scientific Corporation
(the "Company") (NYSE: BSX) today announced that American Medical
Systems Europe B.V., its wholly owned finance subsidiary, has
priced a public offering of €750,000,000 aggregate principal amount
of 3.375% notes due 2029 and €1,250,000,000 aggregate principal
amount of 3.500% notes due 2032 (collectively, the "Notes"). The
Notes will be fully and unconditionally guaranteed by the Company.
The offering is being made pursuant to a registration statement
filed with the U.S. Securities and Exchange Commission.
The offering is expected to close on February 27, 2024, subject to customary closing
conditions. The Company intends to use the net proceeds from the
offering, together with borrowings under its commercial paper
program and cash on hand, to finance the purchase price of the
Company's previously announced agreement to acquire Axonics, Inc.
and to pay related fees and expenses and, to the extent that the
net proceeds from the offering of the Notes are not used for such
purposes, to fund the repayment at maturity of the Company's 3.450%
senior notes due March 2024 and to
pay accrued and unpaid interest with respect to such notes, and for
general corporate purposes.
Nothing herein shall constitute an offer to sell or the
solicitation of an offer to buy the securities, nor shall there be
any sale of the securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
qualification under the securities laws of any such state or
jurisdiction. The offering is being made by means of a prospectus
and related preliminary prospectus supplement only, copies of which
or information concerning this offering may be obtained by
contacting the joint book-running managers: Barclays Bank PLC,
toll-free at 1-888-603-5847; Citigroup Global Markets Europe AG,
toll-free at 1-800-831-9146; or Société Générale, toll-free at
1-855-881-2108.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical technologies that improve the
health of patients around the world. As a global medical technology
leader for more than 40 years, we advance science for life by
providing a broad range of high-performance solutions that address
unmet patient needs and reduce the cost of health care. Our
portfolio of devices and therapies helps physicians diagnose and
treat complex cardiovascular, respiratory, digestive, oncological,
neurological and urological diseases and conditions. Learn more at
www.bostonscientific.com and connect on LinkedIn and X, formerly
Twitter.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements are
based on our beliefs, assumptions and estimates using information
available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements
include, among other things, statements regarding the proposed
offering and intended use of proceeds. If our underlying
assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially
from the expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could
affect our ability to implement our business strategy and may cause
actual results to differ materially from those contemplated by the
forward-looking statements expressed in this press release. As a
result, readers are cautioned not to place undue reliance on any of
our forward-looking statements.
Risks and uncertainties that may cause such differences include,
among other things: economic conditions, including the impact of
foreign currency fluctuations; future U.S. and global political,
competitive, reimbursement and regulatory conditions; geopolitical
events; manufacturing, distribution and supply chain disruptions
and cost increases; disruptions caused by cybersecurity events;
disruptions caused by public health emergencies or extreme weather
or other climate change-related events; labor shortages and
increases in labor costs; variations in outcomes of ongoing and
future clinical trials and market studies; new product
introductions and the market acceptance of those products; market
competition for our products; expected pricing environment;
expected procedural volumes; the closing and integration of
acquisitions; demographic trends; intellectual property rights;
litigation; financial market conditions; the execution and effect
of our restructuring program; the execution and effect of our
business strategy, including our cost-savings and growth
initiatives; our ability to achieve environmental, social and
governance goals and commitments; and future business decisions
made by us and our competitors. New risks and uncertainties may
arise from time to time and are difficult to predict. All of these
factors are difficult or impossible to predict accurately and many
of them are beyond our control. For a further list and description
of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item 1A – Risk Factors in
our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II,
Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we will
file hereafter. We disclaim any intention or obligation to publicly
update or revise any forward-looking statements to reflect any
change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this press release.
CONTACTS:
Emily Anderson
Media Relations
(617) 515-2000 (office)
Emily.Anderson2@bsci.com
Lauren Tengler
Investor Relations
(508) 683-4479
BSXInvestorRelations@bsci.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-pricing-of-2-0-billion-of-senior-notes-302069473.html
SOURCE Boston Scientific Corporation